Pleriksafor

Pleriksafor
Klinički podaci
Drugs.com	Monografija
Način primene	Subkutano
Farmakokinetički podaci
Poluvreme eliminacije	4,4 h
Identifikatori
CAS broj	110078-46-1
ATC kod	L03AX16 (WHO)
PubChem	CID 65015
IUPHAR/BPS	844
DrugBank	DB06809
ChemSpider	58531
ChEBI	CHEBI:120346
ChEMBL	CHEMBL18442
Hemijski podaci
Formula	C28H54N8
Molarna masa	502,782
	SMILES C(N1CCCNCCNCCCNCC1)C1=CC=C(CN2CCCNCCNCCCNCC2)C=C1; ;
	InChI InChI=1S/C28H54N8/c1-9-29-15-17-31-13-3-21-35(23-19-33-11-1)25-27-5-7-28(8-6-27)26-36-22-4-14-32-18-16-30-10-2-12-34-20-24-36/h5-8,29-34H,1-4,9-26H2 ; Key:YIQPUIGJQJDJOS-UHFFFAOYSA-N ;
Fizički podaci
Tačka topljenja	1.315 °C (2.399 °F)

Pleriksafor je organsko jedinjenje, koje sadrži 28 atoma ugljenika i ima molekulsku masu od 502,782 Da.^[1]^[2]^[3]^[4]^[5]^[6]^[7]^[8]^[9]

Osobine

Osobina	Vrednost
Broj akceptora vodonika	8
Broj donora vodonika	6
Broj rotacionih veza	4
Particioni koeficijent^[10] (ALogP)	-0,5
Rastvorljivost^[11] (logS, log(mol/L))	-6,3
Polarna površina^[12] (PSA, Å²)	78,7

Reference

^ Uy GL, Rettig MP, Cashen AF: Plerixafor, a CXCR4 antagonist for the mobilization of hematopoietic stem cells. Expert Opin Biol Ther. Uy, G. L.; Rettig, M. P.; Cashen, A. F. (новембар 2008). . „Plerixafor, a CXCR4 antagonist for the mobilization of hematopoietic stem cells”. Expert Opinion on Biological Therapy. 8 (11): 1797—804. PMID 18847313. doi:10.1517/14712598.8.11.1797.
^ Fricker SP: A novel CXCR4 antagonist for hematopoietic stem cell mobilization. Expert Opin Investig Drugs. Fricker, S. P. (новембар 2008). . „A novel CXCR4 antagonist for hematopoietic stem cell mobilization”. Expert Opinion on Investigational Drugs. 17 (11): 1749—60. PMID 18922110. doi:10.1517/13543784.17.11.1749.
^ DiPersio JF, Stadtmauer EA, Nademanee A, Micallef IN, Stiff PJ, Kaufman JL, Maziarz RT, Hosing C, Fruehauf S, Horwitz M, Cooper D, Bridger G, Calandra G: Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood. Dipersio, J. F.; Stadtmauer, E. A.; Nademanee, A.; Micallef, I. N.; Stiff, P. J.; Kaufman, J. L.; Maziarz, R. T.; Hosing, C.; Früehauf, S.; Horwitz, M.; Cooper, D.; Bridger, G.; Calandra, G. (јун 2009). . „Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma”. Blood. 113 (23): 5720—6. PMID 19363221. doi:10.1182/blood-2008-08-174946. . Epub 2009 Apr 10.
^ Stewart DA, Smith C, MacFarland R, Calandra G: Pharmacokinetics and pharmacodynamics of plerixafor in patients with non-Hodgkin lymphoma and multiple myeloma. Biol Blood Marrow Transplant. 2009 Jan; Stewart, D. A.; Smith, C.; MacFarland, R.; Calandra, G. (2009). . „Pharmacokinetics and pharmacodynamics of plerixafor in patients with non-Hodgkin lymphoma and multiple myeloma”. Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation. 15 (1): 39—46. PMID 19135941. doi:10.1016/j.bbmt.2008.10.018.
^ Brave M, Farrell A, Ching Lin S, Ocheltree T, Pope Miksinski S, Lee SL, Saber H, Fourie J, Tornoe C, Booth B, Yuan W, He K, Justice R, Pazdur R: FDA review summary: Mozobil in combination with granulocyte colony-stimulating factor to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation. Oncology. 2010;78(3-4):282-8. Epub 2010 Jun 8. Brave, M.; Farrell, A.; Ching Lin, S.; Ocheltree, T.; Pope Miksinski, S.; Lee, S. L.; Saber, H.; Fourie, J.; Tornoe, C.; Booth, B.; Yuan, W.; He, K.; Justice, R.; Pazdur, R. (2010). . „FDA review summary: Mozobil in combination with granulocyte colony-stimulating factor to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation”. Oncology. 78 (3–4): 282—288. PMID 20530974. doi:10.1159/000315736.
^ Choi HY, Yong CS, Yoo BK: Plerixafor for stem cell mobilization in patients with non-Hodgkin's lymphoma and multiple myeloma. Ann Pharmacother. Choi, H. Y.; Yong, C. S.; Yoo, B. K. (јануар 2010). . „Plerixafor for stem cell mobilization in patients with non-Hodgkin's lymphoma and multiple myeloma”. The Annals of Pharmacotherapy. 44 (1): 117—26. PMID 20009003. doi:10.1345/aph.1M380. . Epub 2009 Dec 15.
^ Keating GM: Plerixafor: a review of its use in stem-cell mobilization in patients with lymphoma or multiple myeloma. Drugs. Keating, Gillian M. (август 2011). . „Plerixafor”. Drugs. 71 (12): 1623—47. PMID 21861545. doi:10.2165/11206040-000000000-00000. ..
^ Knox, C.; Law, V.; Jewison, T.; Liu, P.; Ly, S.; Frolkis, A.; Pon, A.; Banco, K.; Mak, C.; Neveu, V.; Djoumbou, Y.; Eisner, R.; Guo, A. C.; Wishart, D. S. (2011). . „DrugBank 3.0: A comprehensive resource for 'omics' research on drugs”. Nucleic Acids Research. 39 (Database issue): D1035—41. PMC 3013709 . PMID 21059682. doi:10.1093/nar/gkq1126.
^ Wishart, D. S.; Knox, C.; Guo, A. C.; Cheng, D.; Shrivastava, S.; Tzur, D.; Gautam, B.; Hassanali, M. (2008). . „DrugBank: A knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Research. 36 (Database issue): D901—6. PMC 2238889 . PMID 18048412. doi:10.1093/nar/gkm958.
^ Ghose, Arup K.; Viswanadhan, Vellarkad N.; Wendoloski, John J. (1998). . „Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragmental Methods: An Analysis of ALOGP and CLOGP Methods”. The Journal of Physical Chemistry A. 102 (21): 3762—3772. Bibcode:1998JPCA..102.3762G. doi:10.1021/jp980230o.
^ Tetko, I. V.; Tanchuk, V. Y.; Kasheva, T. N.; Villa, A. E. (2001). . „Estimation of aqueous solubility of chemical compounds using E-state indices”. Journal of Chemical Information and Computer Sciences. 41 (6): 1488—1493. PMID 11749573. doi:10.1021/ci000392t.
^ Ertl, P.; Rohde, B.; Selzer, P. (2000). . „Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties”. Journal of Medicinal Chemistry. 43 (20): 3714—3717. PMID 11020286. doi:10.1021/jm000942e.

Literatura

Hardman JG, Limbird LE, Gilman AG (2001). Goodman & Gilman's The Pharmacological Basis of Therapeutics (10. изд.). New York: McGraw-Hill. ISBN 0071354697. doi:10.1036/0071422803.
Thomas L. Lemke; David A. Williams, ур. (2007). Foye's Principles of Medicinal Chemistry (6. изд.). Baltimore: Lippincott Willams & Wilkins. ISBN 0781768799.

Spoljašnje veze

Plerixafor

Molimo Vas, obratite pažnju na važno upozorenje
u vezi sa temama iz oblasti medicine (zdravlja).

[1] Uy GL, Rettig MP, Cashen AF: Plerixafor, a CXCR4 antagonist for the mobilization of hematopoietic stem cells. Expert Opin Biol Ther. Uy, G. L.; Rettig, M. P.; Cashen, A. F. (новембар 2008). . „Plerixafor, a CXCR4 antagonist for the mobilization of hematopoietic stem cells”. Expert Opinion on Biological Therapy. 8 (11): 1797—804. PMID 18847313. doi:10.1517/14712598.8.11.1797.

[2] Fricker SP: A novel CXCR4 antagonist for hematopoietic stem cell mobilization. Expert Opin Investig Drugs. Fricker, S. P. (новембар 2008). . „A novel CXCR4 antagonist for hematopoietic stem cell mobilization”. Expert Opinion on Investigational Drugs. 17 (11): 1749—60. PMID 18922110. doi:10.1517/13543784.17.11.1749.

[3] DiPersio JF, Stadtmauer EA, Nademanee A, Micallef IN, Stiff PJ, Kaufman JL, Maziarz RT, Hosing C, Fruehauf S, Horwitz M, Cooper D, Bridger G, Calandra G: Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood. Dipersio, J. F.; Stadtmauer, E. A.; Nademanee, A.; Micallef, I. N.; Stiff, P. J.; Kaufman, J. L.; Maziarz, R. T.; Hosing, C.; Früehauf, S.; Horwitz, M.; Cooper, D.; Bridger, G.; Calandra, G. (јун 2009). . „Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma”. Blood. 113 (23): 5720—6. PMID 19363221. doi:10.1182/blood-2008-08-174946. . Epub 2009 Apr 10.

[4] Stewart DA, Smith C, MacFarland R, Calandra G: Pharmacokinetics and pharmacodynamics of plerixafor in patients with non-Hodgkin lymphoma and multiple myeloma. Biol Blood Marrow Transplant. 2009 Jan; Stewart, D. A.; Smith, C.; MacFarland, R.; Calandra, G. (2009). . „Pharmacokinetics and pharmacodynamics of plerixafor in patients with non-Hodgkin lymphoma and multiple myeloma”. Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation. 15 (1): 39—46. PMID 19135941. doi:10.1016/j.bbmt.2008.10.018.

[5] Brave M, Farrell A, Ching Lin S, Ocheltree T, Pope Miksinski S, Lee SL, Saber H, Fourie J, Tornoe C, Booth B, Yuan W, He K, Justice R, Pazdur R: FDA review summary: Mozobil in combination with granulocyte colony-stimulating factor to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation. Oncology. 2010;78(3-4):282-8. Epub 2010 Jun 8. Brave, M.; Farrell, A.; Ching Lin, S.; Ocheltree, T.; Pope Miksinski, S.; Lee, S. L.; Saber, H.; Fourie, J.; Tornoe, C.; Booth, B.; Yuan, W.; He, K.; Justice, R.; Pazdur, R. (2010). . „FDA review summary: Mozobil in combination with granulocyte colony-stimulating factor to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation”. Oncology. 78 (3–4): 282—288. PMID 20530974. doi:10.1159/000315736.

[6] Choi HY, Yong CS, Yoo BK: Plerixafor for stem cell mobilization in patients with non-Hodgkin's lymphoma and multiple myeloma. Ann Pharmacother. Choi, H. Y.; Yong, C. S.; Yoo, B. K. (јануар 2010). . „Plerixafor for stem cell mobilization in patients with non-Hodgkin's lymphoma and multiple myeloma”. The Annals of Pharmacotherapy. 44 (1): 117—26. PMID 20009003. doi:10.1345/aph.1M380. . Epub 2009 Dec 15.

[7] Keating GM: Plerixafor: a review of its use in stem-cell mobilization in patients with lymphoma or multiple myeloma. Drugs. Keating, Gillian M. (август 2011). . „Plerixafor”. Drugs. 71 (12): 1623—47. PMID 21861545. doi:10.2165/11206040-000000000-00000. ..

[8] Knox, C.; Law, V.; Jewison, T.; Liu, P.; Ly, S.; Frolkis, A.; Pon, A.; Banco, K.; Mak, C.; Neveu, V.; Djoumbou, Y.; Eisner, R.; Guo, A. C.; Wishart, D. S. (2011). . „DrugBank 3.0: A comprehensive resource for 'omics' research on drugs”. Nucleic Acids Research. 39 (Database issue): D1035—41. PMC 3013709 . PMID 21059682. doi:10.1093/nar/gkq1126.

[9] Wishart, D. S.; Knox, C.; Guo, A. C.; Cheng, D.; Shrivastava, S.; Tzur, D.; Gautam, B.; Hassanali, M. (2008). . „DrugBank: A knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Research. 36 (Database issue): D901—6. PMC 2238889 . PMID 18048412. doi:10.1093/nar/gkm958.

[10] Ghose, Arup K.; Viswanadhan, Vellarkad N.; Wendoloski, John J. (1998). . „Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragmental Methods: An Analysis of ALOGP and CLOGP Methods”. The Journal of Physical Chemistry A. 102 (21): 3762—3772. Bibcode:1998JPCA..102.3762G. doi:10.1021/jp980230o.

[11] Tetko, I. V.; Tanchuk, V. Y.; Kasheva, T. N.; Villa, A. E. (2001). . „Estimation of aqueous solubility of chemical compounds using E-state indices”. Journal of Chemical Information and Computer Sciences. 41 (6): 1488—1493. PMID 11749573. doi:10.1021/ci000392t.

[12] Ertl, P.; Rohde, B.; Selzer, P. (2000). . „Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties”. Journal of Medicinal Chemistry. 43 (20): 3714—3717. PMID 11020286. doi:10.1021/jm000942e.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

[11]

[12]